Filing Flows › Fortress Biotech (FBIO) › Q2 2026 › vs Q2 2025
Fortress Biotech (FBIO) Q2 2026 vs Q2 2025 (year over year)
Fortress Biotech's revenue rose $2.3M (+14%) from $16.4M in Q2 2025 to $18.7M in Q2 2026. The biggest changes: Journey +$3.5M (+23%).
Fortress Biotech, Q2 2026: revenue $18.7M (+14% year over year), operating margin -53.5%, net earnings $602K, operating cash flow −$59.3M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Journey | $18.5M | $15.0M | $3.5M | +23% |
| Revenue | $18.7M | $16.4M | $2.3M | +14% |
| Other income, net | $10.9M | $24.8M | −$13.9M | -56% |
| Costs & expenses | $29.6M | $52.9M | −$23.2M | -44% |
| Operating costs | $28.7M | $52.9M | −$24.2M | -46% |
| Income tax | $320K | $0 | $320K | — |
| Net earnings | $602K | −$11.7M | $12.3M | — |
| Cost of revenue | $6.1M | $4.9M | $1.2M | +24% |
| Research & development | $805K | $8.1M | −$7.3M | -90% |
| SG&A | $20.8M | $38.8M | −$17.9M | -46% |
| Other operating costs | $969K | $1.1M | −$95K | -9% |
| Operating cash sources | $63.8M | $33.9M | $30.0M | +88% |
| Depreciation & amortization | $1.1M | $1.2M | −$95K | -8% |
| Share-based compensation | $2.9M | $16.8M | −$13.9M | -83% |
| Cash used in operations | $59.3M | $27.6M | $31.7M | +115% |
| Working capital & other | $63.8M | $33.9M | $30.0M | +88% |
Questions
How much did Fortress Biotech's revenue grow year over year in Q2 2026?
Fortress Biotech's revenue rose $2.3M (+14%) from $16.4M in Q2 2025 to $18.7M in Q2 2026.
What drove Fortress Biotech's revenue change in Q2 2026?
Journey +$3.5M (+23%).